A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study
Taiga Otsuka, Tsuyoshi Shirakawa, Mototsugu Shimokawa, Futa Koga, Yasunori Kawaguchi, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Masaru Fukahori, Yoshinobu Okabe, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Taro Shibuki, Kenta Nio, Yasushi Ide, Toshihiko Mizuta, Kenji Mitsugi, Norio Ureshino
Topics & Concepts
FOLFIRINOXMedicineGemcitabinePancreatic cancerInternal medicineIrinotecanOxaliplatinGastroenterologyHazard ratioPerformance statusRetrospective cohort studyCancerConfidence intervalSurgeryOncologyColorectal cancerPancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentCholangiocarcinoma and Gallbladder Cancer Studies